In this issue:
- Diagnostic and prognostic parameters for ICI-related myocarditis
- ICI-associated CV toxic effects
- Haemophagocytic lymphohistiocytosis associated with ICI use
- ICI-related neurotoxicity: incidence and management
- Long-term ICI toxicities
- ICI-induced autoimmune related adverse events
- Tocilizumab for ICI associated arthritis treatment, and prevention on rechallenge
- ICI-associated haematological toxicities and thrombosis risk
- Pembrolizumab-related toxicity in advanced melanoma
- Long-term cognitive function after ICIs for melanoma
Please login below to download this issue (PDF)